MCRB
MCRB
NASDAQ · Biotechnology

Seres Therapeutics Inc

$3.52
+0.00 (+0.00%)
As of Sep 28, 10:21 PM ET ·
Financial Highlights (FY 2026)
Revenue
867.7K
Net Income
6.26M
Gross Margin
—
Profit Margin
721.9%
Rev Growth
-71.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 56.5% 56.5%
Operating Margin -1,683.9% -1,515.5% 15.1% 14.3%
Profit Margin 721.9% 685.8% 11.6% 9.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 867.7K 3.06M 47.44M 44.02M
Gross Profit — — 26.82M 24.89M
Operating Income -14,610,577 -46,333,753 7.15M 6.28M
Net Income 6.26M 19.85M 5.52M 4.21M
Gross Margin — — 56.5% 56.5%
Operating Margin -1,683.9% -1,515.5% 15.1% 14.3%
Profit Margin 721.9% 685.8% 11.6% 9.6%
Rev Growth -71.6% -71.6% +12.6% +20.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 29.85M 36.89M
Total Equity — — 62.46M 70.73M
D/E Ratio — — 0.48 0.52
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -10,060,019 -33,675,186 8.75M 8.39M
Free Cash Flow — — 3.59M 3.32M